Number of pages: 100 | Report Format: PDF | Published date: 23 January, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
US$ 1028 million |
Revenue forecast in 2030 |
US$ 4,808.94 million |
Growth Rate |
CAGR of 18.7% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Historical Years |
2020 |
Segments covered |
Products & Services, Technology, Application, End-users, and Region. |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Based on the deep-dive market assessment study by Growth Plus Reports, the global Whole Exome Sequencing market was valued at US$ 1,028 million in 2021 and is expected to register a revenue CAGR of 18.70% to reach US$ 4,808.94 billion by 2030.
Market Fundamentals
The exome is usually defined as the sequence encompassing all exons of protein-coding genes and nonprotein coding elements such as microRNA or lncRNA. Whole-exome sequencing (WES) is a popular approach for sequencing the bulk of the genome's coding sections, which include most disease-causing mutations. The clinical uses of whole exome sequencing are not just limited to diagnosis. The technology can be used to assist in the therapy for a patient based on their mutation profile. Whole exome sequencing solutions can also be used to estimate an individual’s risk of developing a disease, such as type 2 diabetes (T2D), Miller Syndrome or Alzheimer’s disease, reducing the disease risks.
[253463]
Market Dynamics
The global whole exome sequencing market is an emerging industry expected to illustrate rapid growth during the projected period. The revenue growth of the whole exome sequencing market can be majorly attributed to growing prevalences of genetic diseases and/or hereditary illnesses. For instance, whole exome sequencing is useful for the focused treatment of complicated disorders such as autism spectrum disorder, neuropathy, epilepsy, and other hereditary diseases. The whole exome sequencing approach allows for an in-depth analysis of around 23,000 genes in the human genome in a single run using next-generation sequencing. Additionally, the growing demand for whole exome sequencing among researchers due to growing research and development activities in genomic research positively influences the market growth. The whole exome sequencing market revenue growth is also driven by the demand for personalized medicines or therapies that have gained momentum in the recent years.
Market Ecosystem
The global whole exome sequencing market is analyzed from five perspectives: Products & Services, Technology, Application, End-users, and Region.
Whole Exome Sequencing Market by Products & Services
[215235]
Based on products & services, the global whole exome sequencing market is segmented into systems, kits, and services.
The systems segment is further segmented into Hiseq series (Hiseq 2500 and 1500), ION torrent platform (ION PGM and ION proton), and Miseq. Similarly, the remaining other segments are further sub-segmented into kits: library preparation kits, DNA fragmentation, end repair, a-tailing & size selection kits, and target enrichments kits; and services: sequencing series, bioinformatics (data analysis) services, and others.
The system segment accounts for the largest share of the exome sequencing market expected to register notable revenue growth during the forecast period. The dominance of this segment can be attributed to increased demand for whole exome sequencing systems among healthcare practitioners due to ongoing advancements in bioinformatics visualization capabilities. Sequence analysis provides a wide range of services, such as experimental design, library construction from a wide range of samples, and downstream DNA sequencing, contributing to the segment's growth. Furthermore, the ever-increasing popularity of these systems among researchers and scientists to resolve various bioinformatic-related challenges encouraged the growth of this segment, further driving the market forward.
Whole Exome Sequencing Market by Technology
Based on technology, the global whole exome sequencing market is segmented into ION semiconductor sequencing, sequencing by synthesis (SBS), and others (pyrosequencing, sequencing by ligation (SBL)).
Sequencing by synthesis (SBS) dominates the market with the largest revenue shares owing to its extensive utilization. Among other technologies, the sequencing by synthesis method, which is also known as next-generation sequencing (NGS), plays a significant role in sequencing data (code for proteins or exons). In recent years, healthcare practitioners in various economies have also widely adopted this technology to analyze the potential structural abnormalities in the fetus/neonatal. SBS provides an effective sequence and can sequence hundreds to thousands of genes or gene regions simultaneously. The advantages of sequencing by synthesis technology, such as higher sensitivity for the detection of low-frequency variants (1,2), the lower limit of detection (4,5), wide-ranging genomic coverage, and large capacity with multiplexing, are responsible for its enormous demand.
Whole Exome Sequencing Market by Application
Based on the application, the global whole exome sequencing market is segmented into diagnostics (monogenic (mendelian) disorder, monogenic diabetes, cancer diagnostics, others), drug discovery & development, personalized medicine, animal & agricultural research, and others.
Personalized medicine accounted for the largest revenue share in 2021. The increasing cancer cases across the globe, causing a hike in demand for customized therapies, are driving the personalized medicine segment growth. Onse such example is the increasing utilization of NGS (SBS) in various applications of pharmacogenomics, majorly in oncology for developing tailored drugs/therapies with high efficiency and reduced side effects.
Whole Exome Sequencing Market by End-User
Based on the end-users, the global whole exome sequencing market is segmented into hospitals and clinics, research institutes and academics, pharmaceutical companies, diagnostic centers, and others.
Research institutes and academics lead the whole exome sequencing market with the largest revenue share. Growing research activities and the rapid launch of advanced technologies are the major factors responsible for the growth of this segment. For instance, Avesthagen Limited, India's pioneer industry in systems biology genomics, launched a novel product called AVGEN Diagnostics in 2022. This product is the first fully integrated end-to-end individualized genetic testing service technology using the most recent next generation sequencing technology and AI-powered precision analytics to power diagnostic testing services.
Whole Exome Sequencing Market by Region
Based on the region, the global whole exome sequencing market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
The growing prevalence of chronic and genetic illnesses, rising need for personalized treatment, increasing use of whole exome sequencing technology for the development of improved diagnostics, and increased genomic R&D activities are the important drivers of North America whole exome sequencing market revenue growth. Increased government support for cancer research and the presence of significant players in the region are also driving revenue growth.
The Asia Pacific region is expected to register significant growth during the projected period owing to the factors such as the growing prevalence of chronic and/or genetic diseases among the population and technological advancement. Additionally, the rapid development of the Asia-Pacific area can be linked to increasing per capita income and government efforts to enhance healthcare quality.
Strategic Development
Competitive Landscape
The prominent players operating in the global whole exome sequencing market are:
The sequencing by the synthesis (SBS) segment dominates the global whole exome sequencing market with the largest revenue share in 2021.
The global whole exome sequencing market will grow at a CAGR of 18.7% during the projected period.
Asia Pacific is projected to be the fastest-growing regional market for whole exome sequencing.
Illumina Inc., Eurofins Genomics Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Macrogen Inc., and Roche NimbleGen Inc. are among the key companies operating in the global market .
The expected market size of the whole exome sequencing market is US$ 4,808.94 million in 2030.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.